These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 28797845)

  • 1. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
    Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
    Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in
    Chatterjee S; Huang EH; Christie I; Kurland BF; Burns TF
    Mol Cancer Ther; 2017 May; 16(5):793-804. PubMed ID: 28167505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
    Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
    Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
    Acquaviva J; Smith DL; Sang J; Friedland JC; He S; Sequeira M; Zhang C; Wada Y; Proia DA
    Mol Cancer Ther; 2012 Dec; 11(12):2633-43. PubMed ID: 23012248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
    Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
    Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.
    Djuzenova CS; Fiedler V; Katzer A; Michel K; Deckert S; Zimmermann H; Sukhorukov VL; Flentje M
    Oncotarget; 2016 Jun; 7(25):38191-38209. PubMed ID: 27224913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress.
    Wang CY; Guo ST; Wang JY; Liu F; Zhang YY; Yari H; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Cancer Ther; 2016 Mar; 15(3):448-59. PubMed ID: 26832792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
    Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
    Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS.
    Caiola E; Brunelli L; Marabese M; Broggini M; Lupi M; Pastorelli R
    Oncotarget; 2016 Aug; 7(32):51462-51472. PubMed ID: 27283493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
    Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
    Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of Wild-type
    Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
    Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
    Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
    Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
    Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
    BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.